IRMD CFO John Glenn Buys Shares Amid Institutional Changes
CFO John Glenn bought 5,796 shares of IRMD, marking insider activity amidst institutional adjustments.
Key Points
- IRMD CFO John Glenn purchased 5,796 shares on June 20, 2026, as part of insider transactions.
- Shares of IRMD traded near $91.69 on Tuesday, with institutional investors like BlackRock reducing their holdings.
- Analysts from Roth MKM and Lake Street maintain a 'buy' rating with targets ranging from $55.0 to $72.0.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Glenn, the CFO of IRMD, recently purchased 5,796 shares of the company on June 20, 2026. This transaction did not occur under a pre-planned trading arrangement, highlighting a direct insider move.
Other Institutional Activity in IRMD
Institutional investors have also been active with IRMD shares. BlackRock, Inc. reduced its position by 34,212 shares, leaving it with 967,787 shares valued at approximately $93.16 million. Similarly, Renaissance Technologies LLC trimmed its holdings by 15,700 shares, resulting in 440,712 shares worth about $42.42 million. Copeland Capital Management, LLC cut its stake by 53,225 shares, now holding 359,325 shares valued at $34.59 million. In contrast, Vanguard Capital Management LLC opened a new position with 358,620 shares, while Kayne Anderson Rudnick Investment Management LLC increased its holdings by 16,087 shares, totaling 349,316 shares valued at around $33.63 million.
Insider Buying and Selling at IRADIMED CORPORATION
In addition to John Glenn's purchase, he also sold 5,796 shares on the same day, along with an additional 2,319 shares at an average price of $92.20. These transactions were not part of a pre-planned trading program. Other insiders have been selling as well; Hilda Frederique Scharen-Guivel sold 3,000 shares at $95.00 on June 4, 2026. Roger Susi, the CEO, President, and Chairman, executed planned sales of 2,500 shares each on June 1 and May 27, 2026, at prices of $90.60 and $91.95, respectively.
Analysts Set New Price Targets
Analysts have been optimistic about IRMD. On February 14, 2025, Roth MKM reiterated a 'buy' rating with a price target of $72.00. Lake Street also maintained a 'buy' rating, with a target of $60.00 on June 17, 2024. The consensus remains positive, with multiple analysts recommending a 'buy'.
Bottom Line
The recent insider buying by CFO John Glenn suggests a personal vote of confidence in IRMD. Meanwhile, institutional investors have been adjusting their positions, with some reducing and others increasing their stakes. Analysts continue to see potential in IRMD, maintaining favorable ratings and targets. As always, it's important to remember that these insider and institutional moves, along with analyst ratings, provide insights but do not guarantee future performance.
Get IRADIMED CORPORATION alerts
New 13F filings, insider trades, and analyst moves on $IRMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.